Role of clinical judgement in offering adjuvant chemotherapy for Breast Cancer patients in conjunction with tumour profiling test - Oncotype Dx: a single breast unit experience

被引：0
|
作者：
Patnam, Varun [1 ]
Pushdary, Kamal [1 ]
Leaver, Nick [1 ]
机构：
[1] Whiston Hosp, Prescot, England
来源：
BRITISH JOURNAL OF SURGERY | 2020年 / 107卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
WSP 17.6
引用
收藏
页码：59 / 59
页数：1
相关论文
共 50 条
  • [31] GENE EXPRESSION PROFILING FOR GUIDING ADJUVANT CHEMOTHERAPY DECISIONS IN WOMEN WITH EARLY BREAST CANCER: A COST-EFFECTIVENESS ANALYSIS OF 1000 STRATEGIES FOR THE PROVISION OF ADJUVANT! ONLINE, ONCOTYPE DX AND CHEMOTHERAPY
    Paulden, M.
    Franek, J.
    Pham, B.
    Krahn, M.
    VALUE IN HEALTH, 2011, 14 (03) : A167 - A167
  • [32] Predictors of adjuvant chemotherapy for breast cancer patients with an intermediate Oncotype-DX score: A SEER-based population study.
    Goranta, Sowmya
    Haykal, Tarek
    Bala, Areeq
    AI-Dulaimi, Raqheed
    Bachuwa, Ghassan
    Pandit, Trailokva Nath
    Danish, Rizwan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016
    Schwedhelm, Thomas M.
    Rees, Judy R.
    Onega, Tracy
    Zipkin, Ronnie J.
    Schaefer, Andrew
    Celaya, Maria O.
    Moen, Erika L.
    BMC CANCER, 2020, 20 (01)
  • [34] The Use of Oncotype DX in Adjuvant Chemotherapy Decision-making in Early Breast Cancer Patients with Intermediate Risk of Mortality at 10 Years
    Ramessur, A.
    Harper-Wyne, C.
    Burcombe, R.
    Jyothirmayi, R.
    CLINICAL ONCOLOGY, 2017, 29 (06) : E103 - E103
  • [35] The Role of Oncotype DX® Recurrence Score in Predicting Axillary Response After Neoadjuvant Chemotherapy in Breast Cancer
    Jaime A. Pardo
    Betty Fan
    Alessandra Mele
    Stephanie Serres
    Monica G. Valero
    Isha Emhoff
    Amulya Alapati
    Ted A. James
    Annals of Surgical Oncology, 2021, 28 : 1320 - 1325
  • [36] THE ONCOLOGY NURSE'S ROLE IN THE ADJUVANT TREATMENT OF EARLY STAGE BREAST CANCER: STREAMLINING THE PROCESS OF ORDERING ONCOTYPE DX BREAST CANCER ASSAY
    Warnke, JoEllen
    Roberto, Kathleen
    ONCOLOGY NURSING FORUM, 2010, 37 (03) : E211 - E211
  • [37] EFFECTS ON HEALTH AND COSTS OF DELAYED IMPLEMENTATION OF THE ONCOTYPE DX® TEST FOR ELIGIBLE BREAST CANCER PATIENTS
    Appelberg, K.
    Wilking, N.
    Levin, L. A.
    VALUE IN HEALTH, 2024, 27 (12) : S72 - S72
  • [38] Role of Oncotype DX® recurrence score in predicting nodal response after neoadjuvant chemotherapy in breast cancer
    Mele, Alessandra
    Alapati, Amulya
    James, Ted
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : 172 - 172
  • [39] Clinical outcomes of breast cancer patients with intermediate oncotype DX recurrence scores (RS): A review of the Cleveland Clinic Experience
    Goodman, Lindsey M.
    Montero, Alberto J.
    Rybicki, Lisa
    Mrazeck, Karen
    Calhoun, Benjamin
    Tubbs, Raymond
    Moore, Halle
    CANCER RESEARCH, 2015, 75
  • [40] The impact of Oncotype DX testing on adjuvant chemotherapy decision making in 1-3 node positive breast cancer
    Malam, Yogeshkumar
    Rabie, Mohamed
    Geropantas, Konstantinos
    Alexander, Susanna
    Pain, Simon
    Youssef, Mina
    CANCER REPORTS, 2022, 5 (08)
12345